Olanzapine is widely prescribed for treating schizophrenia and other mental disorders, although it leads to severe body weight gain/obesity. Chronic co-treatment with betahistine has been found to significantly decrease olanzapine-induced weight gain; however, it is not clear whether this co-treatment affects the therapeutic effects of olanzapine. This study investigated the effects of chronic treatment of olanzapine and/or betahistine on the binding density of the serotonergic 5-HT 2A (5-HT 2A R) and 5-HT 2C (5-HT 2C R) receptors, 5-HT transporter (5-HTT), and dopaminergic D 2 receptors (D 2 R) in the brain regions involved in antipsychotic efficacy, including the prefrontal cortex (PFC), cingulate cortex (Cg), nucleus accumbens (NAc), and caudate putamen (CPu). Rats were treated with olanzapine (1 mg/kg, t.i.d.) or vehicle for 3.5 weeks, and then olanzapine treatment was withdrawn for 19 days. From week 6, the two groups were divided into 4 groups (n = 6) for 5 weeks' treatment: (1) olanzapine-only (1 mg/kg, t.i.d.), (2) betahistine-only (9.6 mg/kg, t.i.d.), (3) olanzapine and betahistine cotreatment (O + B), and (4) vehicle. Compared to the control, the olanzapine-only treatment significantly decreased the bindings of 5-HT 2A R, 5-HT 2C R, and 5-HTT in the PFC, Cg, and NAc. Similar changes were observed in the rats receiving the O + B co-treatment. The olanzapine-only treatment significantly increased the D 2 R binding in the Cg, NAc, and CPu, while the betahistine-only treatment reduced D 2 R binding. The co-treatment of betahistine reversed the D 2 R bindings in the NAc and CPu that were increased by olanzapine. Therefore, chronic O + B co-treatment has similar effects on serotonin transmission as the olanzapine-only treatment, but reverses the D 2 R that is up-regulated by chronic olanzapine treatment. The co-treatment maintains the therapeutic effects of olanzapine but decreases/prevents the excess weight gain.
Introduction
Second-generation antipsychotic drugs (SGAs) such as olanzapine have improved tolerability compared with first-generation antipsychotic drugs (FGAs) as they produce fewer extrapyramidal symptoms (EPS) (Leucht et al., 2009 ). However, SGAs, such as olanzapine, can induce severe body weight gain and obesity side effects (Deng, 2013; Lambert, 2011) . For example, the CATIE (The Clinical Anti-psychotic Trials of Intervention Effectiveness) study reported that olanzapine caused significant weight gain (N 7% from baseline) in the highest proportion of chronic schizophrenia patients (30%) and amount of weight gain (average 0.9 kg/month) over an 18-month period, compared with quetiapine (16% and 0.23 kg/month, respectively), risperidone (14% and 0.18 kg/month, respectively), and ziprisidone (7% and 0.14 kg/month, respectively) (Lieberman et al., 2005) . Furthermore, the CAFE (Comparison of Atypical Anti-psychotics for First Episode) study showed that 80% of olanzapine-treated patients had significant weight gain (average, 1.76 kg/month), compared with 57.6% of risperidone (average, 1.28 kg/month), and 50% of quetiapine (average, (Lian et al., 2013; Nasrallah, 2008) . Among these receptors, the dopamine D 2 and 5-HT 2 receptors play critical roles in the therapeutic effects of olanzapine and other SGAs (Ginovart and Kapur, 2012; Meltzer and Massey, 2011 
